onesource

Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
Cyber One, Unit No. 902, Sector 30A
Plot No - 4 & 6, Vashi, Navi Mumbai
400703 India
F: +91 22 2789 2924
T: 91 22 2789 2942

Date: July 24, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 **Scrip Code: 544292**	**National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 **Symbol: ONESOURCE**

Dear Madam/ Sir,

Sub: Press Release:

Please find enclosed herewith Press Release (along with Earnings presentation) issued by the Company titled:

OneSource Announces Strong Q1FY27 Results
Revenue up 37% YoY and EBITDA up 39% YoY

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

A. TRISHA Digitally signed by A. TRISHA
Date: 2026.07.24 19:36:11 +05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl. as above

OneSource Announces Strong Q1FY27 Results
Revenue up 37% YoY and EBITDA up 39% YoY

Performance Highlights

- Revenue of ₹4,490m, up 37% YoY and 5% QoQ, driven by growth in semaglutide commercial launch, new MSA contracts, and customer wins across businesses
- EBITDA of ₹1,233m, up 39% YoY and 34% QoQ, with margins expanding to 27.5%, driven by operating leverage on higher semaglutide revenue
- Adjusted PAT stood at ₹637m with adjusted EPS of ₹5.6

FY28 Guidance Reaffirmation

- $400 million in organic revenue with 40% EBITDA margin

Bangalore, India, July 24, 2026 – OneSource Specialty Pharma Limited *(BSE:544292, NSE: ONESOURCE)* today announced its consolidated financial results for the quarter ended June 30, 2026.

Financial Highlights (In ₹ million)

Particulars	Q1FY27	Q4FY26	QoQ	Q1FY26	YoY
Revenues	4,490	4,282	5%	3,273	37%
EBITDA	1,233	919	34%	885	39%
EBITDA %	27.5%	21.5%	600bps	27.0%	43bps
Adjusted PAT	637	390	63%	371	72%
Adjusted EPS	5.6	3.4	63%	3.2	71%

Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Q1FY27: ₹43m, Q4FY26: gain ₹0.3m, Q1FY26: ₹29m) and scheme related intangible amortisation (₹344m in each quarter)

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, "*We have started FY27 on a strong note, delivering robust growth in revenue and EBITDA, driven by commercialisation of semaglutide in Canada and India. We are excited to bring our second cartridge line into commercial operations in Q2, a significant milestone in our capacity expansion. Our biologics business gathered further momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated CDMO capabilities.*"

Detailed investor communication on the performance of the Company is attached.

About OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

Institutional Investors	Corporate Communication
Anurag Bhagania CFO **Tejaswani Fotedar** +91 9004331391 Email: investor-relations@onesourcecdmo.com	**Pallavi Panchmatia:** +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com **Abhilash Mukherjee:** +91 89044 28907 Email: abhilash.mukherjee@onesourcecdmo.com **Harsh Sheth**: +91 9870631557 Email: harsh.sheth@mslgroup.com

onesource

THE NEW WAY TO CDMO

Investor Presentation | Q1FY27

July 24th, 2026

Safe Harbor Statement

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward- looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Strong start to FY27 as semaglutide commercialisation scales and biologics gains momentum

(Q1FY27 Performance Snapshot)

₹4,490m $47.5m	Revenue	▲ 5% QoQ	▲ 37% YoY
₹1,233m $13.1m	EBITDA	▲ 34% QoQ	▲ 39% YoY
27.5%	EBITDA margin	▲ 600 bps QoQ	▲ 43 bps YoY
₹637m $6.7m	Adjusted PAT[1]	▲ 63% QoQ	▲ 72% YoY

"We have started FY27 on a strong note, delivering robust growth in revenue and EBITDA, driven by commercialisation of semaglutide in Canada and India. We are excited to bring our second cartridge line into commercial operations in Q2, a significant milestone in our capacity expansion. Our biologics business gathered further momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated CDMO capabilities."

Neeraj Sharma
CEO & MD

Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹94.507
[1] Adjusted PAT excludes exceptional items (Q1FY27: ₹43m) and scheme related intangible amortisation (Q1FY27: ₹344m)

Q1FY27: Semaglutide ramp-up delivering 39% YoY EBITDA growth

In $m	Q1FY27	QoQ	Q1FY26	YoY
Revenue	**47.5**	+5%	34.6	+37%
EBITDA	**13.1**	+34%	9.4	+39%
EBITDA margin (%)	**27.5%**	+600bps	27.0%	+43bps
Reported PAT	**2.6**	5x+	(0.0)	Loss to Profit
Adjusted PAT[1]	**6.7**	+63%	3.9	+72%
Adjusted EPS[1] ($)	**0.06**	+63%	0.03	+71%

In ₹m	Q1FY27	QoQ	Q1FY26	YoY
Revenue	**4,490**	+5%	3,273	+37%
EBITDA	**1,233**	+34%	885	+39%
EBITDA margin (%)	**27.5%**	+600bps	27.0%	+43bps
Reported PAT	**250**	5x+	(2)	Loss to Profit
Adjusted PAT[1]	**637**	+63%	371	+72%
Adjusted EPS[1] (₹)	**5.6**	+63%	3.2	+71%

Notes: All figures presented in $ have been converted using average exchange rate of USD = ₹94.507 and accordingly the prior period figures have been restated

[1] Adjusted PAT and Adjusted EPS excludes exceptional items (Q1FY27: ₹43m, Q1FY26: ₹29m) and scheme related intangible amortisation (₹344m in each quarter)

Financial Snapshot

- **Revenue of $47.5m/₹4,490m**
  ↑5% QoQ and ↑37% YoY
  driven by growth in semaglutide commercial launch, new MSA contracts, and customer wins across businesses

- **EBITDA of $13.1m/₹1,233m**
  ↑ 34% QoQ and ↑ 39% YoY
  with margins expanding to **27.5%,** driven by operating leverage on higher semaglutide revenue

Business & Operational Updates

Q1FY27

onesource

Expanded customer base, advanced capacity expansion, and deepened our biologics footprint

Q1FY27 AT A GLANCE

Commercial momentum

Expanding customer engagement across modalities, supported by a robust and growing opportunity pipeline

11
New wins

70+
Active RFPs in pipeline

6
New logos added, bringing total customers to 80+

9
New launches across customers and modalities

Expanding DDC capacity

2nd cartridge line commercialising in Q2
Progressing in line with our capacity expansion plan

2x
'Sterile production days'[1]

Building biologics business

Signed a strategic biosimilars partnership
Funnel at all time high

4x
RFP funnel growth vs FY25

Continuing quality excellence

Stellar compliance track record maintained
EU GMP, TGA GMP received across 2 sites

12
Regulatory inspections and customer audits

DDC = Drug Device Combination
[1.] Total number of production days available across all lines

onesource

Strong and diverse customer base in semaglutide and 2 First-to-File in tirzepatide reinforce our leadership in GLP-1

20+

CUSTOMERS ACROSS DDC PORTFOLIO

First and only CDMO with 3 G7 semaglutide approvals

Supplying multiple partners across key off-patent semaglutide markets, spanning Global Leaders, Regional Players and Country Champions

DDC Semaglutide

CANADA — *#1 GLOBAL OFF-PATENT MARKET / LAUNCHED*

3/3 customer approvals

2 already launched

INDIA — *DAY-1 MARKET LAUNCH*

Multiple partners

10/21 generic pen brands supplied by us

MENA — *LAUNCHING SOON*

Hikma

One of the largest pharma players in MENA

DDC Others

TIRZEPATIDE

2 First-to-File in US

Secured by 2 customers

BIOLOGICS DDC

1st commercial supply to Europe

End-to-end development and manufacturing

LIRAGLUTIDE

New logo added

Strong wallet share expansion potential

MENA = Middle East and North Africa; G-7 which includes Canada, France, Germany, Italy, Japan, the UK and the US

Increased capacity availability → New customers additions, new MSAs signings and contract extensions

Capacity expansion on track with 2nd line commercialising in Q2

End-to-end integrated DDC platform

01


Cartridge filling

Aseptic fill of drug cartridges on the isolator filling line

02


Visual inspection

Automated and manual checks for particulates and defects

03


Pen assembly

Cartridge integrated into the pen device at assembly stations

04


Labelling

Serialised primary labels applied with vision verification

05


Packaging

Pens cartoned with leaflets and cased into finished packs

Maintaining cold-chain integrity throughout the sterile manufacturing process

- Phase 1 of our capacity expansion near completion → New cartridge line to commercialise in Q2, doubling total ‘sterile production days’
- Phase 2 Line 1 to be installed in FY27, tripling our ‘sterile production days’ for FY28
- 80% of the announced $100m capex program is fully committed

Scaling biologics into a key growth pillar beyond FY28

Capacities and Capabilities

One of the few globally integrated biologics platforms with Drug Substance (DS) and Drug Product (DP) capabilities, expanding capacity across microbial and mammalian systems

MICROBIAL	MAMMALIAN
1 KL	4 KL
+5 KL planned addition	+4 KL planned addition

Growth pillars

Biosimilars

- Two marquee biosimilar partnerships announced, strengthening pipeline visibility
- Strong funnel driven by regulatory tailwinds and customer engagement

Animal Health

- Strategic partnership with a Top 3 global animal health company
- Growing animal health biologics adoption driving CDMO demand

Innovators

- RFP momentum translating into a growing early-stage funnel
- In discussions with multiple leading US and European potential partners

Biosimilars momentum accelerating with marquee new customer win and supportive industry tailwinds

Strong biosimilar tailwinds driving customer engagement

- USFDA guidelines easing biosimilar development pathway
- Global pharma expanding manufacturing footprint to de-risk supply chains
- Upcoming patent expiries expanding biosimilar opportunities

India uniquely positioned as a global biologics manufacturing hub

Recently announced biosimilar partnership

onesource + formycon

onesource	formycon
Integrated DS + DP End-to-end biologics manufacturing expertise	**Robust pipeline** Leading, independent developer of high-quality biosimilars

Combining development expertise and manufacturing excellence to bring affordable biologics to patients worldwide

Scaling softgels and injectables for FY28 and beyond

Capacities and Capabilities

Softgel and sterile injectables capabilities under one CDMO platform, a one-stop solution across dosage forms

SOFTGEL

2.4bn

+1.6bn targeted additions

INJECTABLES

Lyophilisation
High-viscosity PFS

Capability and capacity enhancement

Growth pillars

- Scaling CDMO share beyond captive IP demand, backed by capacity expansion, track record and customer relationships
- Building a differentiated R&D pipeline ahead of patent expiries to capture the expanding addressable opportunity
- Wallet share expansion with key customers through upselling and cross-selling

Business Outlook

Q1FY27

onesource

Reaffirming FY28 outlook of $ 400M organic revenue supported by strong execution and business levers

$ 400M	40%	>50%
Revenue (organic)	Steady state EBITDA margin	Targeted ROCE[1]

STRATEGIC PILLARS FOR OUR GROWTH

DDCs (including GLP-1s)	BIOLOGICS	BASE BUSINESS
Scaling across markets and customers, supported by capacity expansion	Biologics funnel expanding with continued pipeline growth and execution of MSAs	Sterile injectable and softgel platforms expanding through new capability investments and strong repeat business

[1.] Goodwill and Scheme Intangibles arising from the business combination is excluded from the ROCE calculation as it is not reflective of operating performance in the absence of common control. Capital employed excludes new capital investment in progress

onesource

(Q1FY27) earnings call

July
25

Schedule:

Day: Saturday
Date: 25th July 2026
Time: 10:00 AM IST

Speakers:

Neeraj Sharma, CEO & MD
Anurag Bhagania, CFO

Dial In:

+91 22 6280 1372
+91 22 7115 8193

Diamond Pass:

Click here for early registration


onesource
THE NEW WAY TO CDMO
OneSource at a glance

Building a pure-play CDMO platform, distinguished by extensive capabilities and robust financial metrics

onesource

ONE-OF-ITS-KIND	ROBUST MANUFACTURING & COMPLIANCE TRACK RECORD	PRESENCE ACROSS MODALITIES INCLUDING GLP-1	HIGHLY ATTRACTIVE FINANCIAL PROFILE	EXPERT PROFESSIONALS AND SEASONED BOARD
#1 Multi Modality CDMO Platform from India	**5** State-of- the-Art Facilities	**Multiple** Ongoing/Completed DDC Projects	**>30%** FY 2025 – FY2028 Revenue CAGR	**1,600+** Workforce
4 Solid Offerings – DDC[1], Biologics, SGC, and Injectables	**220+** Successful Audits	**80+** Global Customers	**~40%** Steady State EBITDA margins	**Accomplished** Board of Directors

1. DDC: Drug Device Combination

ESG progress validated with ratings and recognition

Latest Rating Updates

NSE Sustainability Ratings & Analytics

73/100

"Leader" category among NSE-listed peers

SES ESG

65.7/100

EcoVadis 64/100 ▲7 in FY25 vs FY24 | Bronze | Top 35%

Environment	67 ▲7
Labour & Human Rights	66 ▲6
Ethics	62 ▲12
Sustainable Procurement	55 ▲5

CDP Maintained the score consecutively for 2 years

Climate Change	B
Water Security	B

Rewards & Recognition

Sustainability Excellence Award	Received the Sustainability Excellence Award at the 5th National Bharat CSR & Sustainability Awards 2025
Workplace & Contractor Safety Management	Selected for Prestigious Safety Awards by the National Safety Council, Karnataka Chapter for outstanding performance in Workplace Safety and Contractor Safety Management (FY24 and FY25)

Our Sustainability Efforts are aligned to Global Frameworks, Certifications, and Standards

Sustainable Development Goals · United Nations Global Compact · Integrated Reporting ‹IR› · ISO · BRSR · CDP · ecovadis onesource | THE NEW WAY TO CDMO

Get in touch with us

REGISTERED AND CORPORATE OFFICE

OneSource Specialty Pharma Ltd

Registered Office:
Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A,
Vashi, Navi Mumbai, Sanpada, Thane,
Maharashtra, India, 400703
T: +91 22 2789 2924
F: +91 22 2789 2942

Corporate Office:
OneSource Specialty Pharma Limited
Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road,
Bengaluru, India, 560076
T: +91 80 6784 0738

www.onesourcecdmo.com

INVESTOR RELATIONS

Investor-relations@onesourcecdmo.com